September 16, 2021
Article
The emergency authorization granted to combination bamlanivimab and etesevimab is the second indicated in this last year.
September 14, 2021
Here are some insights into this upcoming 2021-2022 influenza season as well as concerns of the twindemic and addressing both the seasonal and pandemic viruses simultaneously.
September 09, 2021
The shot will be its NanoFlu/NVX-CoV2373 vaccine using the company’s Matrix-M adjuvant platform.
September 08, 2021
Past research has observed links between cardiovascular disease and influenza infection. Vaccination may benefit at-risk patients.
September 07, 2021
The first participants were vaccinated in the study with Pfizer’s respiratory syncytial virus (RSV) investigational vaccine candidate in adults ages 60 or older.
August 30, 2021
Persons living with HIV are susceptible to TB and also appear at increased risk for infecting strains acquiring rifampicin-resistance.
August 26, 2021
An Israel study estimates vaccinated persons' risk of side effects including myocarditis, relative to the risk brought on by SARS-CoV-2 infection.
August 24, 2021
Video
David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.
Kevin J. Downes, MD, and Contagion® Section Editor Conan MacDougall, PharmD, MAS, BCPS, BCIDP, discuss these important topics as another season approaches.
August 23, 2021
The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.
